Synthetic oligonucleotides constitute an important class of therapeutics developed to treat a variety of indications. Two main synthetic approaches exist for the conjugation of a peptide to an oligonucleotide: parallel and linear.

Most proteinogenic peptides, except for certain hydrophobic sequences, can be synthesized in a linear fashion using solid-phase peptide synthesis (SPPS) methods. However, longer sequences, particularly those exceeding 70 amino acids, typically require alternative techniques for synthesis.

Peptide receptor radionuclide therapy (PRRT) is a targeted therapeutic approach that utilizes peptides to deliver cytotoxic radiation to specific receptors overexpressed on cancer cells.

PEGylation is now a well-established technique in the field of targeted drug delivery systems. As more PEGylated therapeutic agents receive FDA approval, more attention has been given to site-specific PEGylation of discrete or monodispersed PEG chains.

Explore this case study on how our SPPS process optimizations have enabled multi-kilo delivery of a pharmaceutically relevant decapeptide within a challenging timescale, while improving environmental impact and production costs...

Mass spectroscopy-based techniques have evolved as a powerful tool in proteomics. Stable isotope-labeled peptides (SIL peptides) are chemically and physically indistinguishable from their endogenous counterparts with respect to retention time, ionization efficiency, and fragmentation pathways.

Solid-phase peptide synthesis approaches require that the side chains of certain amino acids be protected from undesired reactivity during synthesis. The installation and removal of these protection groups results in a lower atom economy…